New Onset of Inflammatory Bowel Disease in Three Patients Undergoing IL-17A Inhibitor Secukinumab: A Case Series

Am J Gastroenterol. 2019 Jan;114(1):179-180. doi: 10.1038/s41395-018-0422-z.

Authors

Marta Vernero¹, Marco Astegiano¹, Davide Giuseppe Ribaldone²

Affiliations

¹ Department of General and Specialist Medicine, Gastroenterologia-U, Città della Salute e della Scienza di Torino, C.so Bramante 88, 10126, Turin, Italy.
² Division of Gastroenterology, Department of Medical Sciences, Molinette Hospital, University of Turin, Turin, Italy.

PMID: 30429591
DOI: 10.1038/s41395-018-0422-z

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Antibodies, Monoclonal / adverse effects*
Antibodies, Monoclonal, Humanized
Colonoscopy
Diagnosis, Differential
Female
Humans
Inflammatory Bowel Diseases / chemically induced
Inflammatory Bowel Diseases / diagnosis*
Inflammatory Bowel Diseases / pathology
Interleukin-17 / antagonists & inhibitors*
Male
Middle Aged
Psoriasis / drug therapy

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Interleukin-17
secukinumab